Ozzion (Pantoprazole Sodium Sesquihydrate)

Pantoprazole is a proton pump inhibitor that acts on the gastric acid secretion pathway. It is indicated for several acid‑related disorders:

• Gastroesophageal reflux disease (GERD): provides relief of heartburn and promotes healing of erosive esophagitis.
• Erosive esophagitis: heals damaged esophageal lining caused by chronic acid exposure.
• Zollinger‑Ellison syndrome: controls excessive gastric acid production associated with this rare endocrine tumor.
• Peptic ulcer disease (duodenal and gastric ulcers): supports ulcer healing and reduces recurrence risk.
• Helicobacter pylori eradication regimens (as adjunct): enhances effectiveness of antibiotic‑based eradication therapy.

• Pantoprazole sodium sesquihydrate selectively and irreversibly binds to the H+/K+‑ATPase enzyme (the gastric proton pump) on the secretory surface of parietal cells. By inhibiting this final step of acid secretion, it markedly reduces both basal and stimulated gastric acid output, allowing the gastrointestinal mucosa to heal and decreasing acid‑related symptoms.

Pantoprazole is generally well tolerated, but adverse reactions can occur.

Common Side Effects

• Headache: mild to moderate intensity.
• Diarrhea: usually self‑limiting.
• Nausea: occasional and transient.
• Abdominal pain: mild discomfort.
• Flatulence: increased intestinal gas.
• Constipation: occasional bowel habit change.

Serious or Rare Side Effects

• Severe allergic reaction (anaphylaxis): rash, swelling, difficulty breathing.
• Clostridioides difficile infection: persistent watery diarrhea.
• Low magnesium levels (hypomagnesemia): muscle cramps, irregular heartbeat.
• Vitamin B12 deficiency with long‑term use: fatigue, neuropathy.
• Bone fractures (with prolonged therapy): increased risk of hip, wrist, or spine fractures.
• Acute interstitial nephritis: kidney inflammation presenting with fever and rash.

When prescribing pantoprazole, clinicians should consider several safety aspects:

• Assess renal function: dose adjustment may be required in severe impairment.
• Review concomitant medications: potential for altered absorption of drugs that need an acidic environment.
• Monitor long‑term users: watch for signs of vitamin B12 deficiency, magnesium loss, and bone density changes.
• Pregnancy and lactation: use only if clearly needed after risk‑benefit evaluation.
• Contraindications: avoid in patients with known hypersensitivity to pantoprazole or other PPIs.
• Store at below 25°C: keep in the original container, protect from moisture and direct sunlight.

Pantoprazole may affect the pharmacokinetics of several medicines. Awareness of key interactions helps maintain therapeutic effectiveness.

Major Interactions (Avoid)

• Antifungal agents (ketoconazole, itraconazole): reduced absorption and efficacy.
• HIV protease inhibitors (atazanavir, nelfinavir): decreased plasma concentrations.
• Clopidogrel: diminished antiplatelet activity, consider alternative therapy.

Moderate Interactions (Monitor Closely)

• Warfarin: possible increase in INR, monitor coagulation parameters.
• Methotrexate (high dose): reduced renal clearance, watch for toxicity.
• Digoxin: slight increase in serum levels, assess for signs of toxicity.
• Oral contraceptives: may lower hormone levels, advise backup contraception.